StocksMedium•4 November 2026•
1 min read
Genentech Reports Positive Phase III Results for Kidney Disease Drug Sefaxersen
Key Facts
1Genentech, a member of the Roche Group, announced positive Phase III data for the investigational drug sefaxersen in patients with primary IgA nephropathy.
Genentech, a member of the Roche Group, announced positive Phase III data for the investigational drug sefaxersen in patients with primary IgA nephropathy. Benzinga reported that the drug met its primary endpoints in late-stage clinical trials, moving it closer to potential regulatory approval and commercialization.
Data from the IMAgINATION study demonstrated that sefaxersen achieved a statistically significant 43.1% reduction in the urine protein-to-creatinine ratio relative to placebo at 37 weeks. RHHBY closed at $59.17 on November 3, 2026, having reached a day high of $60.58 and a low of $59.13.